Trials / Completed
CompletedNCT04311034
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
A Phase Ib Study to Evaluate the Efficacy and Safety of RC48-ADC for Injection in Subjects With Advanced Non-small Cell Lung Cancer With HER2 Overexpression or HER2 Mutation
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of RC48-ADC for injection in subjects with advanced non-small cell lung cancer with HER2 overexpression or HER2 mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48 | Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended. |
Timeline
- Start date
- 2018-09-26
- Primary completion
- 2021-12-21
- Completion
- 2022-05-30
- First posted
- 2020-03-17
- Last updated
- 2023-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04311034. Inclusion in this directory is not an endorsement.